09887.HK
Nanjing Leads Biolabs Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 36.00
−2.65%Sep 28, 2026, 04:19 UTC
Leads Biolabs' core product Vilisin (opamtisumab, a PD-L1/4-1BB bispecific antibody) received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC).
Source:Aug 24, 2026, 23:17 UTC
Virelizhibo announced that its self-developed drug Weilixin (opartuzumab, PDL1/4-1BB bispecific antibody, LBL-024) has completed the safety run-in phase and entered the expansion stage of a Phase II clinical study for first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Source:Jul 27, 2026, 01:46 UTC
Vielibizhi's CEO Kang Xiaoqiang voluntarily extends the lock-up period for his 7.8746 million H-shares by six months to January 24, 2027.
Source: